GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » EV-to-EBIT

ViewRay (ViewRay) EV-to-EBIT : -0.04 (As of May. 07, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ViewRay EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ViewRay's Enterprise Value is $3.8 Mil. ViewRay's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-103.8 Mil. Therefore, ViewRay's EV-to-EBIT for today is -0.04.

The historical rank and industry rank for ViewRay's EV-to-EBIT or its related term are showing as below:

VRAYQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.04   Med: 0   Max: 0
Current: -0.04

VRAYQ's EV-to-EBIT is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 20.715 vs VRAYQ: -0.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ViewRay's Enterprise Value for the quarter that ended in Mar. 2023 was $638.3 Mil. ViewRay's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-103.8 Mil. ViewRay's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -16.26%.


ViewRay EV-to-EBIT Historical Data

The historical data trend for ViewRay's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay EV-to-EBIT Chart

ViewRay Annual Data
Trend Nov13 Nov14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.88 -3.99 -4.58 -7.91 -7.47

ViewRay Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.67 -3.81 -5.69 -7.47 -6.15

Competitive Comparison of ViewRay's EV-to-EBIT

For the Medical Devices subindustry, ViewRay's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViewRay's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViewRay's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ViewRay's EV-to-EBIT falls into.



ViewRay EV-to-EBIT Calculation

ViewRay's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3.840/-103.796
=-0.04

ViewRay's current Enterprise Value is $3.8 Mil.
ViewRay's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViewRay  (OTCPK:VRAYQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ViewRay's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 ) =EBIT / Enterprise Value (Q: Mar. 2023 )
=-103.796/638.34864
=-16.26 %

ViewRay's Enterprise Value for the quarter that ended in Mar. 2023 was $638.3 Mil.
ViewRay's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViewRay EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ViewRay's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ViewRay (ViewRay) Business Description

Traded in Other Exchanges
N/A
Address
1099 18th Street, Suite 3000, Denver, CO, USA, 80202
ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah officer: SVP, General Counsel C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi 10 percent owner 191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler officer: Chief Commercial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski officer: SVP, Customer Services C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello officer: Chief Financial Officer C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey director, officer: Chief Scientific Officer C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr. officer: Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel director C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts director DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen officer: Chief Financial Officer C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058